TAT - tyrosine aminotransferase Gene

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 6898

About TAT

Cytogenetic location: 16q22.2 Genomic coordinates (GRCh38): 16:71,565,660-71,577,092 (from NCBI)

This gene has 4 transcripts (splice variants), 207 orthologues, 7 paralogues and is associated with 3 phenotypes. Restricted expression toward liver (RPKM 242.2).

Summary

This nuclear gene encodes a mitochondrial protein tyrosine aminotransferase which is present in the liver and catalyzes the conversion of L-tyrosine into p-hydroxyphenylpyruvate. Mutations in this gene cause tyrosinemia (type II, Richner-Hanhart syndrome), a disorder accompanied by major skin and corneal lesions, with possible cognitive disability. A regulator gene for tyrosine aminotransferase is X-linked. [provided by RefSeq, Jul 2008]

TAT Products (1)

mRNA Protein Name
NM_000353.3 NP_000344.1 tyrosine aminotransferase

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables L-tyrosine-2-oxoglutarate transaminase activity IDA
IDA: Inferred from direct assay
7999802 GOA
enables identical protein binding IPI
IPI: Inferred from physical interaction
25502805 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
24722188 GOA
Biological Process GO Annotation Evidence References Source
involved in 2-oxoglutarate metabolic process IDA
IDA: Inferred from direct assay
7999802 GOA
involved in glutamate metabolic process IDA
IDA: Inferred from direct assay
7999802 GOA
involved in tyrosine catabolic process IDA
IDA: Inferred from direct assay
7999802 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

TAT Protein Structure

TAT_ubiq

TAT_ubiq: Aminotransferase ubiquitination site (1 - 40)

Aminotran_1_2

Aminotran_1_2: Aminotransferase class I and II (72 - 434)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 454 a.a.
Protein Preferred Names Protein Names

tyrosine aminotransferase

  • L-tyrosine:2-oxoglutarate aminotransferase

TAT Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method References
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Validated Y2H
32296183
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Y2H Bait-Prey Pool
25910212
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Y2H Array
32296183
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Validated Y2H
25910212
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Y2H Array
25910212
Intra
TAT P17735 UBE3A Homo sapiens Q05086-3
Y2H Prey Pooling
32296183
Intra
TAT P17735 TAT Homo sapiens P17735
Y2H Array
32296183
Intra
TAT P17735 TAT Homo sapiens P17735
Y2H Prey Pooling
32296183
Intra
TAT P17735 TAT Homo sapiens P17735
Y2H Array
31515488
Intra
TAT P17735 TAT Homo sapiens P17735
Y2H Array
25502805
Intra
TAT P17735 TAT Homo sapiens P17735
Validated Y2H
32296183
Intra
TAT P17735 GLUL Homo sapiens P15104
Y2H Array
25910212
Intra
TAT P17735 GLUL Homo sapiens P15104
Y2H Bait-Prey Pool
25910212
Intra
TAT P17735 GLUL Homo sapiens P15104
Validated Y2H
25910212
Cross: Cross-species interaction Intra: Intraspecies interaction

Related Diseases

Diseases Alias
Tyrosinemia, Type Ii

  • Tyrosinemia Type Ii

  • Oculocutaneous Tyrosinemia

  • Richner-Hanhart Syndrome

  • Tyrosine Aminotransferase Deficiency

  • Tat Deficiency

  • Tyrosine Transaminase Deficiency

  • Keratosis Palmoplantaris With Corneal Dystrophy

  • TYRSN2

  • Oregon Type Tyrosinemia

  • Tyrosinemia Type 2

  • Tyrosinosis Oculocutaneous Type

  • Tyrosinosis, Oculocutaneous Type

  • Richner Hanhart Syndrome

  • Keratosis Palmoplantaris-Corneal Dystrophy Syndrome

  • Tyrosinemia Due To Tat Deficiency

  • Tyrosinemia Due To Tyrosine Aminotransferase Deficiency

  • Tyrosinemia 2

  • Tyrosinemia Oregon Type

  • Tyrosine Transaminase Deficiency Disease
Tyrosinemia

  • Hypertyrosinemia

  • Tyrosinemias

  • Hereditary Tyrosinemia

  • Hypertyrosinaemia

  • Tyrosinaemia

  • Hereditary Hypertyrosinemia
Tyrosinemia, Type Iii

  • Tyrosinemia Type Iii

  • 4-Hydroxyphenylpyruvate Dioxygenase Deficiency

  • TYRSN3

  • 4-Hydroxyphenylpyruvic Acid Oxidase Deficiency

  • Tyrosinemia Type 3

  • 4-Alpha Hydroxyphenylpyruvate Dioxygenase Deficiency

  • 4-Alpha Hydroxyphenylpyruvic Acid Oxidase Deficiency

  • Tyrosinemia Due To 4-Hydroxyphenylpyruvate Dioxygenase Deficiency

  • Tyrosinemia Due To 4-Hydroxyphenylpyruvic Acid Oxidase Deficiency

  • Tyrosinemia Due To Hpd Deficiency

  • Tyrosinemia 3
Human Immunodeficiency Virus Type 1

  • Aids

  • Hiv/Aids

  • Aids, Delayed/Rapid Progression To

  • Hiv-1, Susceptibility To

  • Hiv-1 Viremia, Susceptibility To

  • Human Immunodeficiency Virus Type 1, Susceptibility To

  • Hiv-1

  • Aids, Slow Progression To

  • Rapid Progression To Aids From Hiv1 Infection

  • Hiv1 Infection, Resistance To

  • Hiv1 Infection

  • Hiv-1 Viremia

  • Aids, Resistance To

  • Aids, Rapid Progression To

  • Hiv/Aids, Susceptibility To

  • Hiv-1, Resistance To

  • Hiv1, Resistance To

  • Hiv1

  • Hiv-1 Disease, Delayed Progression Of

  • Hiv-1 Disease, Rapid Progression Of

  • Hiv Infection, Resistance To

  • Hiv Type 1, Susceptibility To

  • Hiv Type 1

  • Hiv-1 Infection

  • Human Immunodeficiency Virus I Infection

  • Acquired Immunodeficiency Syndrome

  • Hiv-Infection/Aids
Immune Deficiency Disease

  • Immunodeficiency

  • Primary Immunodeficiency

  • Primary Immunodeficiency Disease

  • Immunologic Deficiency Syndromes

  • Hypoimmunity

  • Immune Deficiency Disorder

  • Immunodeficiency Syndrome

  • Immune Disorder

  • Primary Immune Deficiency Disorder

  • Immune System Diseases

  • Human Immunodeficiency Virus Infection

  • Hiv - [Human Immunodeficiency Virus Infection]

  • Hiv Positive Nos

  • Hiv Disease

  • Acquired Immune Deficiency Syndrome-Related Complex

  • Aids-Like Syndrome

  • Aids-Related Complex Nos

  • Arc - [Aids-Related Complex]

  • Immunodeficiency Due To Human Immunodeficiency Virus Infection

  • Unspecified Human Immunodeficiency Virus Disease

  • Hiv Disease Nos

  • Human Immunodeficiency Virus Positive Nos

  • Hiv Nos

  • Deficiency Of Complement Initial Pathway

  • Deficiency Of Complement Terminal Pathway

  • Cfdd - [Complement Factor D Deficiency]

  • Immunodeficiency With Nk-Cell - [Natural-Killer Cell] Deficiency

  • Nonfamilial Hypogammaglobulinaemia

  • Common Variable Immune Deficiency

  • Nonfamilial Agammaglobulinaemia

  • Common Variable Agammaglobulinaemia

  • Agammaglobulinaemia Nos

  • Agammaglobulinaemia Antibody Deficiency Syndrome

  • Hypogammaglobulinaemia Antibody Deficiency Syndrome

  • Acquired Agammaglobulinaemia Nos

  • Hypogammaglobulinaemia Nos

  • Hyper Igm
Palmoplantar Keratosis

  • Palmoplantar Keratoderma

  • Keratosis Palmaris Et Plantaris

  • Palmo-Plantar Keratodermas

  • Keratoderma, Palmoplantar

  • Keratoderma Palmoplantar

  • Keratoderma, Palmoplantar, Diffuse

  • Hyperkeratosis Of Palms And Soles

  • Palmoplantar Hyperkeratosis
Disseminated Intravascular Coagulation

  • Defibrination Syndrome

  • Dic

  • Diffuse Or Disseminated Intravascular Coagulation

  • Fibrinolytic Purpura

  • Consumption Coagulopathy

  • Diffuse Intravascular Coagulation

  • Dic - [Disseminated Intravascular Coagulation]

  • Disseminated Intravascular Coagulopathy

  • Fibrinolysis Nos

  • Thrombolytic Purpura
Herpes Simplex Virus Keratitis

  • Dendritic Keratitis

  • Keratitis, Dendritic

  • Keratitis, Herpetic
Alkaptonuria

  • Homogentisic Acid Oxidase Deficiency

  • Alcaptonuria

  • AKU

  • Deficiency Of Homogentisicase

  • Homogentisate 1,2-Dioxygenase Deficiency

  • Alkaptonuric Ochronosis

  • Homogentisic Acidura

  • Ochronosis, Hereditary

  • Hereditary Ochronosis

  • Ochronosis

  • Homogentisicaciduria

  • Deficiency Of Homogentisate Oxygenase
Hawkinsinuria

  • 4-Alpha-Hydroxyphenylpyruvate Hydroxylase Deficiency

  • 4-Hppd Deficiency

  • 4-Hydroxyphenylpyruvic Acid Dioxygenase Deficiency

  • HWKS

  • HAWK
Human Immunodeficiency Virus Infectious Disease

  • Hiv Infections
Tyrosinemia, Type I

  • Tyrosinemia Type I

  • Hepatorenal Tyrosinemia

  • Fumarylacetoacetase Deficiency

  • Fah Deficiency

  • TYRSN1

  • Fumarylacetoacetate Hydrolase Deficiency

  • Tyrosinemia Type 1

  • Tyrosinemia 1

  • Fumarylacetoacetase
Keratitis, Hereditary

  • Keratitis

  • Autosomal Dominant Keratitis

  • Hereditary Keratitis

  • Dominantly Inherited Keratitis

  • Keratitis Hereditary

  • KERH
Glutaric Aciduria Iii

  • Glutaryl-Coa Oxidase Deficiency

  • Ga Iii

  • Glutaric Acidemia Type 3

  • GA3

  • Glutaric Aciduria Type 3

  • Glutaric Aciduria 3

  • Glutaric Acidemia Type Iii

  • Glutaric Aciduria Type Iii
Corneal Dystrophy
Progressive Multifocal Leukoencephalopathy

  • Pml

  • Leukoencephalopathy, Progressive Multifocal

  • Progressive Multifocal Leukoencephalitis

  • Leukoencephalopathy Progressive Multifocal

  • Pml - [Progressive Multifocal Leukoencephalopathy]
Ectodermal Dysplasia

  • Congenital Ectodermal Defect

  • Congenital Ectodermal Dysplasia

  • Ectodermal Dysplasia Syndrome

  • Dysplasia, Ectodermal
Amino Acid Metabolic Disorder

  • Amino Acid Metabolism, Inborn Errors

  • Inborn Errors Of Amino Acid Metabolism

  • Disorder Of Amino Acid Metabolism

  • Amino Acid Metabolism Disorders
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B2224 Thiamine disulfide Inhibitor 99.54% Unkown

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-P0117 Tat-NR2B9c Inhibitor 99.89% Phase 3
HY-142118 Trabedersen Inhibitor 91.24% Phase 3
HY-P4056 CIGB-300 / Phase 3
HY-19149 Ro24-7429 99.85% Phase 2
HY-148130 Rugonersen Activator 98.50% Phase 1

Pre-clinical Phase

Bioactive Molecules (140)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P4108 TAT-HA2 Fusion Peptide 99.70% Unkown
HY-P2260 Tat-beclin 1 99.89% Unkown
HY-P5381 gp91 ds-tat 99.00% Unkown
HY-P0281 TAT 99.92% Unkown
HY-P5307 Peptide A5K 99.34% Unkown
HY-P0282A TAT peptide TFA 99.83% Unkown
HY-P2280 TAT-P110 Inhibitor 99.95% Unkown
HY-P10638 TAT-CN21 Inhibitor 99.38% Unkown
HY-P1136C TAT-Gap19 TFA 99.41% Unkown
HY-P1136B TAT-Gap19 99.60% Unkown
HY-P1801A Cys-TAT(47-57) TFA 98.33% Unkown
HY-W104477 3-Fluoro-L-tyrosine 99.99% Unkown
HY-P0281A TAT TFA 99.70% Unkown
HY-P3432 DfTat 99.53% Unkown
HY-P1420 TAT-cyclo-CLLFVY Inhibitor 99.13% Unkown
HY-P1491 HIV-1 TAT (48-60) 99.78% Unkown
HY-126428 ZL0580 99.42% Unkown
HY-P2260B Tat-beclin 1 scrambled 99.10% Unkown
HY-P4125A FITC-LC-TAT (47-57) acetate 99.06% Unkown
HY-P2500 (Arg)9, FAM-labeled 99.67% Unkown
HY-P0117A Tat-NR2B9c TFA Inhibitor 99.66% Unkown
HY-P2259 TAT-GluA2 3Y Inhibitor 99.93% Unkown
HY-P5883 TAT-M2NX Inhibitor 99.55% Unkown
HY-172279A DSPE-PEG2000-TAT 95.0% Unkown
HY-P1575 TAT (48-57) 98.23% Unkown
HY-P4122A TAT (47-57), FAM-labeled acetate / Unkown
HY-P10438 TAT-Braftide Inhibitor 99.52% Unkown
HY-P10436 Braftide Inhibitor 99.51% Unkown
HY-P1328 TAT-14 Activator 99.71% Unkown
HY-P10275 Tat-NTS peptide Inhibitor 99.88% Unkown
HY-P4056A CIGB-300 acetate 99.59% Unkown
HY-P2467 Biotin-TAT (47-57) 98.56% Unkown
HY-P3429A SAMβA TFA Inhibitor 99.13% Unkown
HY-P0281B TAT acetate 98.66% Unkown
HY-P10839 NBD peptide Inhibitor 98.02% Unkown
HY-P4114 TAT-NSF700scr 95.17% Unkown
HY-P10446 TAT-PiET-PROTAC Inhibitor 98.04% Unkown
HY-P10638A TAT-CN21 (scrambled) Control 99.71% Unkown
HY-P10999A INF7TAT-P55 acetate 98.14% Unkown
HY-172279B DSPE-PEG5000-TAT / Unkown
HY-172279C DSPE-PEG3400-TAT / Unkown
HY-P0282 TAT peptide / Unkown
HY-P10358 TAT-CBD3A6K 98.26% Unkown
HY-P10359A TAT-QFNP12 acetate Inhibitor 95.90% Unkown
HY-P10405A TAT-D1 peptide acetate Inhibitor / Unkown
HY-P10824 RI-OR2-TAT Inhibitor / Unkown
HY-P10966A Tat-IKIP (46-60) TFA Inhibitor 99.76% Unkown
HY-P11117 TAT-EE3 Inhibitor 99.89% Unkown
HY-P11219 TAT-PDHPS1 Inhibitor 98.35% Unkown
HY-P2260C Tat-beclin 1 scrambled TFA 96.26% Unkown
HY-P2307 Tat-NR2Baa 96.89% Unkown
HY-P3429 SAMβA Inhibitor 99.14% Unkown
HY-P3730A Cdk2/Cyclin Inhibitory Peptide I acetate Inhibitor 99.61% Unkown
HY-P4106A Tat-GluR23Y, scrambled TFA 99.43% Unkown
HY-P5107A Low molecular weight protamine acetate 98.64% Unkown
HY-P5117 TAT-CIRP Inhibitor 98.32% Unkown
HY-P5320 TAT-BH4 (Bcl-xL) Inhibitor / Unkown
HY-P5754B TAT-NEP1-40 acetate Inhibitor 94.33% Unkown
HY-D2441 TAT-PEG-Cy3 95.0% Unkown
HY-115828 APA-APA-MPO dihydrochloride / Unkown
HY-115829 APA-H-MPO hydrochloride / Unkown
HY-148412 Monarsen Inhibitor / Unkown
HY-156372 AChE-IN-44 Inhibitor / Unkown
HY-172279 DSPE-PEG1000-TAT / Unkown
HY-CE01687 Lys-CoA-tat / Unkown
HY-P0281F Cy5-TAT acetate / Unkown
HY-P10048 TAT-JIP Inhibitor / Unkown
HY-P10049 TAT-TCL1-Akt-in Inhibitor / Unkown
HY-P10074 TAT-MEK1 Inhibitor / Unkown
HY-P10076 TAT-JBD20 Inhibitor / Unkown
HY-P10106 TAT-PAK18 inhibitory peptide Inhibitor / Unkown
HY-P10107 TAT-PAK18 R192A Control / Unkown
HY-P10110 retro-inverso TAT-Beclin 1 (D-amino acid) Inducer / Unkown
HY-P10255 K90-114TAT Inhibitor / Unkown
HY-P10357 TAT-CBD3 Inhibitor / Unkown
HY-P10357A Tat-CBD3 TFA Inhibitor / Unkown
HY-P10359 TAT-QFNP12 Inhibitor / Unkown
HY-P10360 Tat-βsyn-degron Degrader / Unkown
HY-P10445 TAT-PiET Inhibitor / Unkown
HY-P10464 Tat-AKAP79 (326-336) Inhibitor / Unkown
HY-P10465 TRPV1-Tat Antagonist / Unkown
HY-P10797 TAT-N24 Inhibitor / Unkown
HY-P10821 Myr-Tat-PKCβII Inhibitor / Unkown
HY-P10852 TAT-MKK3b Inhibitor / Unkown
HY-P10854 TAT-N15 Inhibitor / Unkown
HY-P10966 Tat-IKIP (46-60) Inhibitor / Unkown
HY-P10977 Tat-ASIC1a (1-20) (mouse, rat) Inhibitor / Unkown
HY-P10995 TAT-327 / Unkown
HY-P10999 INF7TAT-P55 / Unkown
HY-P11000 INF7TAT / Unkown
HY-P11152 HIV-1 tat Protein (1-9) Inhibitor / Unkown
HY-P11222 Tat-SERT-15C Activator / Unkown
HY-P1328A TAT-14 TFA Activator / Unkown
HY-P1420A TAT-cyclo-CLLFVY TFA Inhibitor / Unkown
HY-P1575A TAT (48-57) TFA / Unkown
HY-P1801 Cys-TAT(47-57) / Unkown
HY-P1908 sgp91 ds-tat Peptide 2, scrambled Inhibitor / Unkown
HY-P2260A Tat-beclin 1 TFA / Unkown
HY-P2298 TAT-P4-(DATC5)2 Inhibitor / Unkown
HY-P2298A TAT-P4-(DATC5)2 TFA / Unkown
HY-P2307A Tat-NR2Baa TFA / Unkown
HY-P2493 (Cys47)-HIV-1 tat Protein (47-57) / Unkown
HY-P3730 Cdk2/Cyclin Inhibitory Peptide I Inhibitor / Unkown
HY-P3731 Cdk2/Cyclin Inhibitory Peptide II Inhibitor / Unkown
HY-P4101 Cys(Npys)-TAT (47-57) / Unkown
HY-P4103 Cys(Npys)-TAT (47-57), FAM-labeled / Unkown
HY-P4105 TAT (47-57), TAMRA-labeled / Unkown
HY-P4106 Tat-GluR23Y, scrambled / Unkown
HY-P4108C Cys-TAT-HA2 / Unkown
HY-P4110 TAT-NSF222 Fusion Peptide Inhibitor / Unkown
HY-P4122 TAT (47-57), FAM-labeled / Unkown
HY-P4123 TAT (47-57) GGG-Cys(Npys) Inhibitor / Unkown
HY-P4125 FITC-LC-TAT (47-57) / Unkown
HY-P5277 TAT-GluN2BCTM Degrader / Unkown
HY-P5307A Peptide A5K acetate / Unkown
HY-P5320A TAT-BH4 (Bcl-xL) TFA Inhibitor / Unkown
HY-P5384 sgp91 ds-tat Inhibitor / Unkown
HY-P5395 TAT-GluR23A Fusion Peptide Inhibitor / Unkown
HY-P5754 TAT-NEP1-40 Inhibitor / Unkown
HY-P5754A TAT-NEP1-40 TFA Inhibitor / Unkown
HY-P5874 Myr-TAT-CBD3 Inhibitor / Unkown
HY-P5891 TAT-SAMβA Antagonist / Unkown
HY-P5947 Tat-HA-NR2B9c / Unkown
HY-RS01124 ATAT1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS14225 TAT Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-119120 JTK-101 Inhibitor / Unkown
HY-175534 SRI-45949 Modulator / Unkown
HY-175535 SRI-32743 / Unkown
HY-178439 SARS-CoV-2 3CLpro-IN-33 Inhibitor / Unkown
HY-180187 019854-B06 Inhibitor / Unkown
HY-181831 XQ2 Activator / Unkown
HY-P10358A TAT-CBD3A6K acetate 99.76% Unkown
HY-P10401 TAT-GluR6-9c Antagonist / Unkown
HY-P10405 TAT-D1 peptide Antagonist / Unkown
HY-RS16581 Tat Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS19656 Atat1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23015 Tat Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS26149 Atat1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-P3431 VSGLNPSLWSIFGLQFILLWLVSGSRHYLW Antagonist / Unkown
HY-P3431A VSGLNPSLWSIFGLQFILLWLVSGSRHYLW TFA Antagonist / Unkown

Orthologs Information

Species Symbol Source ID
Canis familiaris TAT VGNC VGNC:53455
Bos taurus TAT VGNC VGNC:35616
Felis catus TAT VGNC VGNC:65965
Mus musculus TAT MGD MGI:98487
Macaca mulatta TAT VGNC VGNC:78100
Rattus norvegicus TAT RGD RGD:3820
Others TAT NCBI